Elena Federzoni

Medicine · Health Sciences

15h-index834citations50works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer-related Molecular Pathways(25), Acute Myeloid Leukemia Research(10), Retinoids in leukemia and cellular processes(9), Cell death mechanisms and regulation(5), Neutrophil, Myeloperoxidase and Oxidative Mechanisms(5)

Publications50 total

Supplementary Figure 4 from Inhibition of GSK3B Bypass Drug Resistance of p53-Null Colon Carcinomas by Enabling Necroptosis in Response to Chemotherapy
2023Open Access
Supplementary Figure 2 from Inhibition of GSK3B Bypass Drug Resistance of p53-Null Colon Carcinomas by Enabling Necroptosis in Response to Chemotherapy
2023Open Access
Supplementary Table 2 from Inhibition of GSK3B Bypass Drug Resistance of p53-Null Colon Carcinomas by Enabling Necroptosis in Response to Chemotherapy
2023Open Access
Data from Inhibition of GSK3B Bypass Drug Resistance of p53-Null Colon Carcinomas by Enabling Necroptosis in Response to Chemotherapy
2023Open Access
Supplementary Table 3 from Inhibition of GSK3B Bypass Drug Resistance of p53-Null Colon Carcinomas by Enabling Necroptosis in Response to Chemotherapy
2023Open Access
Supplementary Figure 6 from Inhibition of GSK3B Bypass Drug Resistance of p53-Null Colon Carcinomas by Enabling Necroptosis in Response to Chemotherapy
2023Open Access
Supplementary Data from Inhibition of GSK3B Bypass Drug Resistance of p53-Null Colon Carcinomas by Enabling Necroptosis in Response to Chemotherapy
2023Open Access
Data from Inhibition of GSK3B Bypass Drug Resistance of p53-Null Colon Carcinomas by Enabling Necroptosis in Response to Chemotherapy
2023Open Access
Supplementary Figure 4 from Inhibition of GSK3B Bypass Drug Resistance of p53-Null Colon Carcinomas by Enabling Necroptosis in Response to Chemotherapy
2023Open Access
Supplementary Figure 3 from Inhibition of GSK3B Bypass Drug Resistance of p53-Null Colon Carcinomas by Enabling Necroptosis in Response to Chemotherapy
2023Open Access
Supplementary Figure 2 from Inhibition of GSK3B Bypass Drug Resistance of p53-Null Colon Carcinomas by Enabling Necroptosis in Response to Chemotherapy
2023Open Access
Supplementary Figure 5 from Inhibition of GSK3B Bypass Drug Resistance of p53-Null Colon Carcinomas by Enabling Necroptosis in Response to Chemotherapy
2023Open Access
Supplementary Figure 3 from Inhibition of GSK3B Bypass Drug Resistance of p53-Null Colon Carcinomas by Enabling Necroptosis in Response to Chemotherapy
2023Open Access
Supplementary Data from Inhibition of GSK3B Bypass Drug Resistance of p53-Null Colon Carcinomas by Enabling Necroptosis in Response to Chemotherapy
2023Open Access
Supplementary Table 3 from Inhibition of GSK3B Bypass Drug Resistance of p53-Null Colon Carcinomas by Enabling Necroptosis in Response to Chemotherapy
2023Open Access
Supplementary Table 2 from Inhibition of GSK3B Bypass Drug Resistance of p53-Null Colon Carcinomas by Enabling Necroptosis in Response to Chemotherapy
2023Open Access
Supplementary Figure 5 from Inhibition of GSK3B Bypass Drug Resistance of p53-Null Colon Carcinomas by Enabling Necroptosis in Response to Chemotherapy
2023Open Access
Supplementary Table 1 from Inhibition of GSK3B Bypass Drug Resistance of p53-Null Colon Carcinomas by Enabling Necroptosis in Response to Chemotherapy
2023Open Access
Supplementary Table 1 from Inhibition of GSK3B Bypass Drug Resistance of p53-Null Colon Carcinomas by Enabling Necroptosis in Response to Chemotherapy
2023Open Access
Supplementary Figure 6 from Inhibition of GSK3B Bypass Drug Resistance of p53-Null Colon Carcinomas by Enabling Necroptosis in Response to Chemotherapy
2023Open Access
page 1 of 3Next →

Frequent Co-authors

Emanuela Grassilli(25), Robert Narloch(25), Kristian Helin(25), Marialuisa Lavitrano(25), Leonarda Ianzano(24), Biagio Eugenio Leone(24), Roberto Giovannoni(23), Laura Masiero(23), Serena Bonin(23), Marisa Donada(23), Giorgio Stanta(23), Fabio Pisano(22), Gabriele Romano(22), Mario P. Tschan(18), Bruce E. Torbett(13), Martin F. Fey(11), Magali Humbert(9), Hans‐Uwe Simon(5), Thomas Kaufmann(4), Peter J.M. Valk(4)